<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="1" offset="0" totalResults="1"><SearchResults><Trial Id="332824"><Indications><Indication>Melanoma</Indication></Indications><CompaniesSponsor><Company>Queensland Government</Company></CompaniesSponsor><DateChangeLast>2018-03-20T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>diphenylcyclopropenone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>58</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The aim of this prospective, non-randomized, single-centre study was to assess the clinical outcomes of diphenylcyclopropenone or diphencyprone (DPCP) in patients with cutaneous in-transit melanoma (ITM) metastases [ 2015078 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><TitleDisplay>A prospective, non-randomized, single-centre study to assess the clinical outcomes of Diphenylcyclopropenone or diphencyprone (DPCP) in patients with cutaneous in-transit melanoma (ITM) metastases</TitleDisplay><PrimaryCompletionDate></PrimaryCompletionDate><NumberOfSites>0</NumberOfSites></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>